Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(8 sites)

United States

University of Alabama at Birmingham School of Medicine: Division of Clinical Immunology & Rheumatology, Birmingham, Alabama

Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia

University of Chicago, Department of Medicine: Rheumatology, Chicago, Illinois

Johns Hopkins Hospital: Division of Rheumatology, Baltimore, Maryland

Mayo Clinic: Division of Rheumatology, Rochester, Minnesota

Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology, Great Neck, New York

University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh, Pennsylvania

University of Texas - Houston, Houston, Texas